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Summary
Background The Gambia introduced seven-valent pneumococcal conjugate vaccine (PCV7) in August 2009, followed 
by PCV13 in May, 2011, using a schedule of three primary doses without a booster dose or catch-up immunisation. We 
aimed to assess the long-term impact of PCV on disease incidence.
Methods We did 10 years of population-based surveillance for invasive pneumococcal disease (IPD) and WHO defined 
radiological pneumonia with consolidation in rural Gambia. The surveillance population included all Basse Health 
and Demographic Surveillance System residents aged 2 months or older. Nurses screened all outpatients and 
inpatients at all health facilities using standardised criteria for referral. Clinicians then applied criteria for patient 
investigation. We defined IPD as a compatible illness with isolation of Streptococcus pneumoniae from a normally 
sterile site (cerebrospinal fluid, blood, or pleural fluid). We compared disease incidence between baseline 
(May 12, 2008–May 11, 2010) and post-vaccine years (2016–2017), in children aged 2 months to 14 years, adjusting for 
changes in case ascertainment over time.
Findings We identified 22 728 patients for investigation and detected 342 cases of IPD and 2623 cases of radiological 
pneumonia. Among children aged 2–59 months, IPD incidence declined from 184 cases per 100 000 person-years to 
38 cases per 100 000 person-years, an 80% reduction (95% CI 69–87). Non-pneumococcal bacteraemia incidence did 
not change significantly over time (incidence rate ratio 0·88; 95% CI, 0·64–1·21). We detected zero cases of 
vaccine-type IPD in the 2–11 month age group in 2016–17. Incidence of radiological pneumonia decreased by 33% 
(95% CI 24–40), from 10·5 to 7·0 per 1000 person-years in the 2–59 month age group, while pneumonia 
hospitalisations declined by 27% (95% CI 22–31). In the 5–14 year age group, IPD incidence declined by 69% (95% CI 
–28 to 91) and radiological pneumonia by 27% (95% CI –5 to 49).
Interpretation Routine introduction of PCV13 substantially reduced the incidence of childhood IPD and pneumonia 
in rural Gambia, including elimination of vaccine-type IPD in infants. Other low-income countries can expect 
substantial impact from the introduction of PCV13 using a schedule of three primary doses.
Funding Gavi, The Vaccine Alliance; Bill & Melinda Gates Foundation; UK Medical Research Council; Pfizer Ltd.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Introduction
Global childhood deaths due to pneumococcal disease are 
estimated to have fallen from 826 000 in 20001 to 318 000 
in 2015.2 Introduction of pneumococcal conjugate vaccines 
(PCV) likely contributed to this decrease. However, despite 
60 low-income countries having introduced PCV, data are 
limited on vaccine impact in these settings.
In South Africa, and Kenya, substantial reductions in 
invasive pneumococcal disease (IPD) were observed 
after the introduction of PCV.3,4 A schedule with 
two primary doses and a booster dose was used in 
South Africa, whereas a three-dose schedule without a 
booster dose was used in Kenya, accompanied by a 
catch-up campaign in children younger than 5 years old. 
However, most low-income countries use a schedule 
with three primary doses without a booster or catch-up 
immunisation, and there is little information on this 
schedule’s effectiveness in these countries.
The Gambia introduced PCV7 into its Expanded 
Program on Immunization (EPI) on August 19, 2009, 
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using three primary doses at ages 2, 3, and 4 months, 
without catch-up immunisation. PCV13 replaced PCV7 
in May, 2011. At the end of 2017, the surveillance system 
in The Gambia completed a 10-year study to measure 
the impact of the introduction of PCV, administered 
according to the standard three-dose schedule adopted 
widely in low-income countries. We previously reported 
the impact of routine infant vaccination with PCV 4 years 
after its introduction and documented modest reductions 
in IPD and radiological pneumonia.5,6 We report now on 
vaccine impact 8 years after the introduction of PCV.
Methods
Surveillance and population
We did population-based surveillance for suspected pneu-
monia, septicaemia, and meningitis in the Basse Health 
and Demographic Surveillance System7 (BHDSS, appendix 
p 6) between May 12, 2008, and Dec 31, 2017. The 
surveillance population included all BHDSS residents 
aged 2 months or older. Here we report findings restricted 
to children aged 2 months to 14 years. The total population 
of the BHDSS in 2017 was 181 740, including 85 279 aged 
2 months to 14 years.
Endpoints
The primary endpoints were IPD and radiological 
pneumonia with consolidation, as defined by WHO.8 We 
defined IPD as a compatible illness with isolation of 
Streptococcus pneumoniae from a normally sterile site 
(cerebrospinal fluid, blood, or pleural fluid). Secondary 
endpoints of clinical and hypoxic pneumonia were 
defined as in our previous report.6 IPD outcomes were 
further categorised according to PCV13 serotype (1, 3, 4, 
5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) or non-PCV13 
serotype. We do not present impact estimates on pneu-
mococcal pneumonia because it is a subgroup of IPD. 
Research in context
Evidence before this study
In high-income and middle-income countries the introduction of 
pneumococcal conjugate vaccine (PCV) into routine 
immunisation programmes has led to significant reductions in 
pneumonia hospitalisations and invasive pneumococcal disease 
(IPD) because of vaccine serotypes. We did a systematic literature 
search of studies of PCV10 and PCV13 effectiveness or impact in 
low-income countries on PubMed, Embase, and Web of Science 
for the period Jan 1, 2008, to Aug 31, 2020. We searched using the 
terms “pneumococcal vaccines” OR “vaccines, pneumococcal 
conjugate” AND “meningitis”, “sepsis”, “septic(a)emia”, “bacter(a)
emia”, “invasive pneumococcal disease”, “pneumonia” AND 
“impact” OR “effectiveness”. We searched for prospective 
population-based studies that included at least 1 year of data 
before PCV introduction and at least 2 years of data after vaccine 
introduction. Two publications reported the impact on IPD and 
pneumonia in The Gambia, 4 and 5 years, after the introduction of 
PCV with the standard schedule of three primary doses without a 
booster dose or catch-up immunisation. In the 2–59 month age 
group, all IPD declined by 55% and radiological pneumonia 
declined by 23%. Two Kenyan publications reported the impact of 
PCV10 introduced using the standard three-dose schedule with 
catch-up immunisation to 5 years of age. In children younger than 
5 years, all IPD declined by 68% and radiological pneumonia 
declined by 48%. In Burkina Faso, modest reductions in 
pneumococcal meningitis were noted 3–4 years after the 
introduction of PCV13, although preexisting temporal trends 
precluded precise estimation of vaccine impact. Despite 
pneumococcal disease being a major cause of child mortality, and 
the introduction of PCV in 60 low-income countries, there are few 
prospective population-based data reporting PCV impact in such 
settings. In particular, there are no data reporting long-term 
impact in a low-income country where PCV was introduced with 
the standard schedule of three primary doses without a booster 
dose and without catch-up immunisation.
Added value of this study
This study provides the first evidence of long-term PCV impact 
when immunisation is introduced with the standard three-dose 
schedule without a booster or catch-up dose, as is the norm in 
almost all low-income countries. 8 years after the introduction of 
PCV7 or PCV13, this 10-year population based surveillance study 
observed a 92% reduction in the incidence of IPD due to vaccine-
types in the 2–59 month age group, an 80% reduction in all IPD 
(greater than the 55% reduction observed after 4 years), and no 
significant change in non-vaccine type IPD. In the final 2 years of 
the study, we observed zero cases of vaccine-type IPD in infants. 
The incidence of radiological pneumonia declined by 33% 
(greater than the 24% reduction after 5 years) and severe hypoxic 
pneumonia declined by 60%. The 27% reduction in hospitalised 
clinical pneumonia was greater than the 8% reduction previously 
reported. There was no change in the incidence of the control 
condition of non-pneumococcal bacteraemia, suggesting the 
reductions in the disease endpoints were related to the 
introduction of PCV. The full impact of vaccination with PCV 
took 8 years to develop.
Implications of all the available evidence
Our findings are widely relevant as the data indicate that 
the routine introduction and long-term use of PCV13 in 
low-income countries will substantially reduce rates of invasive 
pneumococcal disease and severe pneumonia, where the 
burden is greatest. Countries should consider the use of 
catch-up immunisation when PCV is introduced and implement 
long-term surveillance to measure the full impact of the 
introduction of PCV. These results should encourage low-
income countries that have not yet introduced PCV to do so, 
and those that are using PCV should maintain budget support 
for their programmes as they transition from financial support 
from Gavi, the Vaccine Alliance.
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We defined bronchiolitis and vaccine failure as previously 
reported (see full definitions in the appendix).5,6
Procedures
The surveillance methods have been described previously.5–7 
In brief, nurses assessed all outpatients and inpatients at all 
health facilities in the BHDSS using standardised criteria 
for referral to clinicians in Basse (appendix p 24). For 
referred patients, clinicians then applied standardised 
criteria to identify patients with suspected pneumonia, 
septicaemia, or meningitis and requested blood culture, 
lumbar puncture, or chest radiography (appendix pp 25–26). 
Aspiration of pleural fluid or lung aspiration was done for 
selected patients. Each year, rapid malaria tests (ICT 
Diagnostics, Cape Town, South Africa) were done on all 
enrolled patients from August to December (the malaria 
transmission season). Surveillance was interrupted 
between Oct 5 and Nov 3, 2010 because of flooding. Radio-
graphs were done according to WHO recommendations8 
and interpreted by two independent reviewers, with 
readings discordant for radiological endpoint consolidation 
resolved by a third reviewer.
Specimens were processed in Basse with standard 
methods.9 S pneumoniae was identified by colony 
morphology and optochin sensitivity. Pneumococcal 
isolates were serotyped at the WHO Regional Reference 
Laboratory (Medical Research Council Unit The Gambia 
[MRC], Fajara, The Gambia), using latex agglutination 
with factor-specific and group-specific antisera.5 
Serotypes 6A and 6B were differentiated from 6C by PCR.10 
Basse and Fajara laboratories submit to external quality 
assurance (UK National External Quality Assessment 
Service [Sheffield, UK] and OneWorld Accuracy 
International, Canada).
The Gambia Government/MRC Joint Ethics Committee 
(number 1087) and the London School of Hygiene & 
Tropical Medicine ethics committee approved the study. 
Parents or guardians gave written informed consent for all 
surveillance procedures.
Statistical analysis
We calculated annual incidence by dividing the number 
of cases by midpoint population estimates obtained each 
year from the BHDSS. To calculate incidence in 2008 
and 2010, we extrapolated cases and assigned serotype 
groupings for the unobserved periods as described 
previously.5,6
As in our previous IPD analysis,5 we adjusted for 
changes over time in age-specific numbers of patients 
eligible for investigation per unit population by adjusting 
annual IPD counts, assuming the same serotype 
distribution as the observed cases each year. We adjusted 
annual, age-specific counts of IPD to the mean rate of 
enrolment of patients eligible for investigation during 
the study period. As in our previous pneumonia analysis,6 
we adjusted annual case counts for age-specific changes 
over time in the number of patients referred to clinicians 
per unit population. We adjusted annual, age-specific 
counts of pneumonia to the mean rate of referral 
during the study period. Thus, interpretation of adjusted 
analyses assumes a constant rate of enrolment of patients 
eligible for investigation and a constant rate of referral to 
clinicians during the observation period.
Consistent with our previous analyses,5,6 we calculated 
the ratio of the incidence in the last 2 years of surveillance 
(2016–17) compared to the baseline first 2 years 
(May 12, 2008, to May 11, 2010). We used the Poisson 
distribution to calculate incidence rate ratios (IRR) 
with 95% CI. CIs were inflated allowing for over-
dispersion in the 2–23 month (IPD), 2–4 year (radiological 
pneumonia), and 5–14 year (IPD) age groups, estimated 
from an individual-level Poisson regression analysis of 
2008–09 data.
To investigate potential bias due to temporal changes in 
health care seeking, patient investigation, or confounding 
due to secular trends in epidemic serotypes we did three a 
priori stratified analyses, excluding outpatients, cases 
identified by lung aspiration alone, and cases caused by 
serotype 1 or 5. To assess the effect of temporal secular 
trends related to bacterial disease, as control endpoints, 
we evaluated changes in the incidence of non-pneu-
mococcal bacteraemia and non-pneumococcal pneu-
monia. We also evaluated temporal changes in the 
prevalence of contaminated blood cultures, malnutrition, 
and malaria over time.5,6 Statistical significance was set at 
a p value less than 0·05. The data were analysed with Stata 
(version 15.1) and MATLAB (version R2015a).
Role of the funding source
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Coverage of one dose of PCV7 in the 12–23 month age 
group at the end of 2009 was 10%. Coverage of at 
least two doses of PCV13 reached plateaus in 2013 of 
around 55% and 75% in the 2–11 and 12–23 month age 
groups, respectively (appendix p 7). In the 2–4 year age 
group, coverage of at least two doses in 2016–17 was 
about 78%, greater than the 50% coverage in the final 
2 years of surveillance in our earlier report;6 coverage in 
the 5–14 year age group was about 10%. During the 
period 2012–17, coverage of two doses before the ages 
of 4, 5, and 6 months was 42%, 67%, and 77%, respectively, 
and coverage of three doses before 5, 6, and 7 months of 
age was 29%, 50%, and 63%, respectively. In 2016–17 
coverage of three doses before 6 months of age was 59%. 
We assumed that second or third doses of PCV that were 
received more than 24 weeks after the previous dose 
might act as a booster rather than primary dose. 
During 2012–17, 2% of infants received their second 
dose more than 24 weeks after their first dose and 
3% received their third dose more than 24 weeks after 
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their second dose. The low proportion of infants who 
received substantially delayed second or third doses of 
PCV suggest that our results relate to programmatic use 
of a three-dose schedule without booster or catch-up 
dose.
A total of 26 401 patients were screened; 22 728 patients 
aged 2 months to 14 years met criteria for microbiological 
investigation and 21 954 met criteria for radiological 
investigation (figure 1). Surveillance was done at a 
consistently high level (appendix pp 8–12). We identified 
342 cases of IPD and 2623 cases of radiological pneu-
monia. 29 IPD cases (8·5%) died, with 14% mortality 
(14 of 99) in the first year of life (tables 1 and 2). By far 
the largest number of pneumonia deaths occurred in 
those with clinical pneumonia, but mortality in children 
with clinical (2·1%) or radiological pneu monia (2·4%) 
was much lower than mortality in cases of pneumococcal 
pneumonia (8·6%) or hypoxic pneumonia (12·1%).
Crude and adjusted impact estimates for the primary 
endpoints in the 2–59 month age group differed by 10% or 
less, indicating no significant confounding due to changes 
in case ascertainment over time (tables 3 and 4).11 
Comparing the baseline and 2016–17 periods, the adjusted 
incidence of IPD in the 2–59 month age group declined 
from 184 cases per 100 000 person-years to 38 cases 
per 100 000 person-years, an 80% reduction (95% CI 69–87; 
table 3, figure 2). The adjusted incidence of PCV13-type 
IPD declined by 92% (95% CI 83–96), from 147 cases 
per 100 000 person-years to 12 cases per 100 000 person-
years. The adjusted incidence of IPD caused by non-PCV13 
serotypes was 37 cases per 100 000 person-years at baseline 
compared with 24 cases per 100 000 person years in 
2016–17, a 31% reduction that was not significant (95% CI 
–29 to 64).
In the 5–14 year age group, crude and adjusted impact 
estimates differed by more than 10%, suggesting 
significant confounding due to temporal changes in 
case ascertainment.11 The adjusted incidence of all IPD 
among those aged 5–14 years declined by 69% (95% CI 
–28 to 91), from 10 cases per 100 000 person-years to 
3 cases per 100 000 person-years (table 3, appendix p 13). 
In contrast to our earlier report,5 the adjusted incidence 
of PCV13-type IPD in the 5–14 year age group decreased 
by 89% (95% CI 0–99), from 9 cases per 100 000 person-
years to 1 per 100 000 person-years.
The estimates of PCV impact on IPD were unchanged 
in stratified analyses excluding outpatients and cases 
detected only by lung aspiration (appendix pp 27–28). 
When cases due to serotypes 1 or 5 were excluded, 
vaccine impact against PCV13 serotype disease was 
unchanged (appendix p 29). There was no change in the 
adjusted incidence of the control condition of non-
pneumococcal bacteraemia between the baseline and 
2016–17 period in the 2–59 month age group, adjusted 
IRR 0·88 (95% CI 0·64–1·21), nor in the 5–14 year 
age group, adjusted IRR 1·16 (95% CI 0·34–3·91; 
appendix p 30, pp 14–15).
PCV7 showed some impact on IPD in the 2–59 month 
age group from 2011 onwards with reduced cases due to 
serotypes 6A and 14 (appendix p 16). Following 
the introduction of PCV13 in 2011, cases of serotype 5 
declined in 2012 while serotype 1 cases continued 
to be detected until 2014 (appendix p 16). However, 
by 2016–17 the incidence of serotype 1 IPD had 
declined by 94% (95% CI 53–99), from 22 cases 
Figure 1: Study profile
BHDSS=Basse Health and Demographic Surveillance System
22 728 met criteria for microbiology investigation
    9359 age 2–11 months
    6743 age 12–23 months
    5450 age 2–4 years
    1176 age 5–14 years
252 no microbiology investigation
26 401 patients presented to BHDSS health facilities








   71 with no record of having seen clinician
26 111 assessed by clinician
848 resident outside BHDSS
559 age 0–60 days
957 age ≥15 years
1019 not suspected pneumonia,
            septicaemia, or meningitis
   659 not clinical pneumonia, 
            septicaemia, or meningitis
1134 clinical septicaemia or
           meningitis only
22 476 microbiology investigation
    9242 age 2–11 months
    6678 age 12–23 months
    5395 age 2–4 years
    1161 age 5–14 years               
342 cases of IPD               
     99 age 2–11 months        
     91 age 12–23 months                    
     108 age 2–4 years
     44 age 5–14 years
       
22 134 negative for Streptococcus
                 pneumoniae
21 954 met criteria for chest radiograph
    9209 age 2–11 months
    6364 age 12–23 months
    5291 age 2–4 years
    1090 age 5–14 years
    
1789 no chest radiograph
20 165 chest radiographs
    8640 age 2–11 months
    5937 age 12–23 months
    4608 age 2–4 years
    980 age 5–14 years
2623 cases of endpoint consolidation
            950 age 2–11 months
            713 age 12–23 months
            656 age 2–4 years
            304 age 5–14 years
17 528 no endpoint consolidation
        14 undetermined radiographs
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to 1 case per 100 000 person-years. We detected zero 
cases of IPD due to PCV13 serotypes in 2016–17 in the 
2–11 month age group (appendix p 18). 15 different 
serotypes contributed to a peak of non-vaccine type IPD 
in 2014; such cases then declined (appendix p 17).
In the 5–14 year age group there was a peak of 
serotype 5 IPD in 2010 with zero cases in 2016–17 
(appendix p 17). Serotype 1 cases persisted for a greater 
period but became rare in 2016–17. There were eight 
cases of PCV13-type IPD in the 5–14 year age group in 
the first 2 years of surveillance (all serotype 1 or 5) and 
one case in 2016–17 (aIRR 0·11, 95% CI 0·01–1·00). 
Across all age groups, there were 27 episodes of vaccine 
failure: three for serotypes 1 and 19A, five for serotype 
23F, and eight for serotype 14 (appendix p 31).
Following the introduction of PCV7 and PCV13 the 
incidence of radiological pneumonia initially fell, how-
ever a peak then occurred in 2015 in the 2–23 month age 
All IPD (342) PCV7 (73)* PCV13 only (139)* Non-vaccine type 
(128)*
Age
2–11 months 99 (29%) 17 (23%) 12 (9%) 67 (52%)
12–23 months 91 (27%) 27 (37%) 36 (26%) 29 (23%)
2–4 years 108 (32%) 26 (36%) 55 (40%) 27 (21%)
5–14 years 44 (13%) 3 (4%) 36 (26%) 5 (4%)
Male 196 (57%) 41 (56%) 82 (59%) 70 (55%)
Female 146 (43%) 32 (44%) 57 (41%) 58 (45%)
Diagnostic category†
Meningitis 40 (12%) 11 (15%) 10 (7%) 19 (15%)
Septicaemia 101 (30%) 11 (15%) 34 (24%) 54 (42%)
Pneumonia 201 (59%) 51 (70%) 95 (68%) 55 (43%)
Pathology
Meningitis 24 (7%) 8 (11%) 3 (2%) 13 (10%)
Non-meningitis 318 (93%) 65 (89%) 136 (98%) 115 (90%)
Weight-for-height z-score‡ less than –3 52/298 (17%) 14/70 (20%) 11/103 (11%) 26/123 (21%)
Treated as inpatient 304 (89%) 63 (86%) 132 (95%) 21 (84%)
Deaths 29 (8%) 6 (8%) 8 (6%) 15 (12%)
Proven meningitis 8 (2%) 4 (5%) 0 4 (3%)
Non-meningitis 21 (6%) 2 (3%) 8 (6%) 11 (9%)
Data are n (%). IPD=invasive pneumococcal disease. PCV7=serotypes covered by the 7-valent PCV: 4, 6B, 9V, 14, 18C, 19F, 23F, and cross-reactive 6A. PCV13 only=serotypes 
covered only by the 13-valent PCV: 1, 3, 5, 7F, and 19A. Non-vaccine type=serotypes not covered by PCV13. *The number of episodes PCV7, PCV13 only, and non-vaccine type 
IPD do not sum to 342 cases; in three cases there were two different serotypes detected in different samples and in five cases the isolate could not be serotyped. †Categories 
of surveillance diagnosis (appendix) are mutually exclusive and ranked by severity; meningitis most severe, then septicaemia, and pneumonia. ‡Defined using the 2006 WHO 
anthropometry standards, age 2–59 months.










2–11 months 9209 (42·0%) 950 (36·2%) 97 (28·8%) 419 (52·3%)
12–23 months 6364 (28·0%) 713 (27·2%) 89 (26·4%) 210 (26·2%)
2–4 years 5291 (24·1%) 656 (25·0%) 107 (31·8%) 145 (18·1%)
5–14 years 1090 (5·0%) 304 (11·6%) 44 (13·1%) 27 (3·4%)
Male 12 334 (56·2%) 1427 (54·4%) 193 (57·3%) 415 (51·8%)
Female 9620 (43·8%) 1196 (45·6%) 144 (42·7%) 386 (48·2%)
Weight-for-height z-score¶ less than  –3 2447/20 864 (11·7%) 337/2319 (14·5%) 50/293 (17·1%) 129/774 (16·7%)
Treated as inpatient 12 812 (58·4%) 2166 (82·6%) 301 (89·3%) 749 (93·5%)
Mortality 467 (2·1%) 63 (2·4%) 29 (8·6%) 97 (12·1%)
Data are n (%) or n/N (%). *Defined as acute cough or shortness of breath with raised respiratory rate for age, inability to feed or sit, reduced conscious state, convulsions, lower 
chest wall in-drawing, peripheral arterial oxygen saturation <93%, dull chest percussion note, or bronchial breathing on auscultation. †Defined as the WHO standard for 
childhood radiological pneumonia with consolidation. ‡Defined as clinical pneumonia with isolation of Streptococcus pneumoniae from a normally sterile site. §Defined as clinical 
pneumonia with peripheral arterial oxygen saturation <90% at presentation. ¶Defined by the 2006 WHO anthropometry standards, age 2–59 months.
Table 2: Characteristics of cases of pneumonia by type between May 12, 2008, and Dec 31, 2017
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group. Incidence in all age groups then declined 
(figure 2). The adjusted incidence of radiological 
pneumonia in the 2–59 month age group decreased 
from 10·5 to 7·0 per 1000 person-years, a 33% reduction 
(95% CI 24 to 40). Reductions in radiological pneumonia 
were greatest in the 2–4 year age group (table 4). The 
adjusted reduction in radiological pneumonia in the 
5–14 year age group was 27% (95% CI –5 to 49), 
from 0·7 per 1000 person-years to 0·5 per 1000 person-
years (table 4, appendix p 19).
Compared to our earlier findings,6 we observed greater 
impact on the following pneumonia endpoints. The 
adjusted incidence of clinical pneumonia in the 
2–59 month age group declined by 5% (95% CI 1–9), 
from 68·8 per 1000 person-years to 65·1 per 1000 person-
years (table 4). Hospitalised clinical pneumonia fell 
by 27% (95% CI 22–31), from 43·1 per 1000 person-years 
to 31·5 per 1000 person-years, with the greatest absolute 
reduction being in the 2–11 month age group, with a fall 
from 105·3 per 1000 person-years to 79·1 per 1000 person-
years, a 25% decline (95% CI 18 to 31).
There was a 60% (95% CI 51–68) decline in the 
adjusted incidence of hypoxic pneumonia in the 
2–59 month age group, from 4·7 per 1000 person-years 
to 1·9 per 1000 person-years. S pneumoniae was isolated 
from 168 (21·0%) of 801 cases of hypoxic pneumonia 
and 337 (1·5%) of 21 954 clinical pneumonia cases. 
The adjusted incidence of the control condition of 
non-pneumococcal bacterial pneumonia was not 
significantly different in the baseline and 2016–17 
periods (appendix p 36). The adjusted incidence of 
bronchiolitis declined by 31% (95% CI 22–39) in the 
2–11 month age group and 21% (95% CI 6–33) in 
12–23 month age group (appendix p 36).
The prevalence of malaria in patients across all age 
groups fluctuated between 6% and 19% between 2008 
and 2016 and fell to 3% in 2017 (appendix p 20). 
The prevalence of malnutrition and blood culture 
contamination was stable throughout (appendix pp 21–22).
Discussion
Using population-based surveillance over 10 years, we 
found large reductions in IPD and moderate reductions 
in pneumonia incidence in young children after intro-
duction of PCV13 using the standard three-dose schedule 
without booster or catch-up dose. Notably, in the 
Baseline adjusted 
(crude) cases
Baseline adjusted (crude) 




2016–17 adjusted (crude) 
incidence per 100 000 
person-years
Crude IRR 2016–17 vs 
baseline (95% CI)
Adjusted IRR 2016–17 vs 
baseline (95% CI)
Age 2–23 months
All 62 (50) 281 (226) 20 (18) 71 (63) 0·28 (0·16–0·48) 0·25 (0·15–0·42)
PCV7 29 (23) 129 (104) 2 (2) 7 (7) 0·07 (0·02–0·30) 0·06 (0·01–0·23)
PCV13 47 (38) 213 (171) 6 (5) 20 (17) 0·10 (0·04–0·26) 0·09 (0·04–0·24)
PCV13 only 20 (16) 89 (72) 4 (3) 12 (10) 0·14 (0·04–0·51) 0·14 (0·05–0·46)
Non-vaccine type 15 (12) 67 (54) 15 (13) 51 (45) 0·83 (0·37–1·87) 0·76 (0·37–1·61)
Age 2–4 years
All 38 (33) 118 (102) 7 (6) 16 (13) 0·13 (0·04–0·31) 0·13 (0·06–0·30)
PCV7 15 (13) 46 (40) 1 (1) 2 (2) 0·05 (0·001–0·37) 0·05 (0·007–0·37)
PCV13 33 (29) 103 (90) 4 (3) 8 (7) 0·07 (0·01–0·24) 0·08 (0·03–0·23)
PCV13 only 19 (17) 60 (53) 3 (2) 6 (4) 0·08 (0·009–0·35) 0·09 (0·02–0·34)
Non-vaccine type 5 (4) 15 (12) 4 (3) 8 (6) 0·54 (0·08–3·16) 0·54 (0·14–2·11)
Age 2–59 months
All 100 (83) 184 (153) 28 (24) 38 (32) 0·21 (0·14–0·33) 0·20 (0·13–0·31)
PCV7 43 (36) 79 (66) 3 (3) 4 (4) 0·06 (0·02–0·20) 0·05 (0·02–0·17)
PCV13 80 (67) 147 (123) 9 (8) 12 (11) 0·09 (0·04–0·18) 0·08 (0·04–0·17)
PCV13 only 39 (33) 72 (61) 6 (5) 8 (7) 0·11 (0·04–0·29) 0·11 (0·05–0·27)
Non-vaccine type 20 (16) 37 (29) 18 (16) 24 (22) 0·74 (0·37–1·47) 0·69 (0·36–1·29)
Age 5–14 years
All 9 (10) 10 (12) 4 (3) 3 (3) 0·23 (0·05–0·98) 0·31 (0·09–1·28)
PCV7 0 (0) ·· 0 (0) ·· ·· ··
PCV13 8 (9) 9 (11) 1 (1) 1 (1) 0·09 (0·008–0·87) 0·11 (0·009–1·00)
PCV13 only 8 (9) 9 (11) 1 (1) 1 (1) 0·09 (0·008–0·87) 0·11 (0·009–1·00)
Non-vaccine type 1 (1) 1 (1) 2 (2) 2 (2) 1·53 (0·10–22·9) 1·53 (0·10–22·9)
The baseline period was May 12, 2008 to May 11, 2010. Numbers of serotype-specific IPD cases may not sum to the number of all IPD cases due to five isolates that could not be serotyped. Case counts are 
adjusted for trends in patients eligible for investigation and rounded to the nearest integer. CIs calculated taking into account over-dispersed Poisson distributions in the 2–23 months and 5–14 years age groups.  
IPD=invasive pneumococcal disease. IRR=incidence rate ratio. PCV7=serotypes covered by PCV7: 4, 6B, 9V, 14, 18C, 19F, 23F, and cross-reactive 6A. PCV13=serotypes covered by PCV13. PCV13 only=serotypes 
covered by PCV13 but not PCV7: 1, 3, 5, 7F, and 19A. Non-vaccine type=serotypes not covered by PCV13.
Table 3: Number of cases and incidence of IPD in the baseline period and 2016–17 after vaccine introduction
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2–11 month age group we observed zero vaccine-type 
cases in 2016–17. This is the first population-based study 
of the long-term impact of the introduction of PCV with 
the approach that is employed in almost all low-income 
countries.
The introduction of PCV in high-income countries has 
been associated with large reductions in IPD12–14 and 
substantial falls in pneumonia admissions.15–17 Early 
studies of the impact of PCV13 in South Africa3 and The 
Gambia5,6 reported moderate effects but longer-term 
observation has been needed to determine the full 
programmatic impact. A recent series of papers 
examining data from the WHO-coordinated Paediatric 
Bacterial Meningitis Surveillance in a number of African 
countries indicates early changes in meningitis and 
pneumonia epidemiology associated with the introduction 
of PCV, but calculations of incidence before and after 
introduction were not available.18 In Basse, 8 years after 
the introduction of PCV, we observed a 92% reduction in 
PCV13-type IPD in the 2–59 month age group, and 
Baseline adjusted 
(crude) cases





2016–17 adjusted (crude) 
incidence per 
1000 person-years
Crude IRR 2016–17 vs 
baseline (95% CI)
Adjusted IRR 2016–17 vs 
baseline (95% CI)
Age 2–11 months
Radiological pneumonia with 
consolidation
215 (180) 20·7 (17·3) 233 (177) 17·9 (13·6) 0·79 (0·64–0·97) 0·87 (0·72–1·04)
Hospitalised radiological 
pneumonia with consolidation
184 (154) 17·7 (14·8) 178 (137) 13·7 (10·5) 0·71 (0·56–0·90) 0·77 (0·63–0·95)
Clinical pneumonia 1708 (1426) 164·2 (137·1) 2021 (1615) 155·3 (124·1) 0·91 (0·84–0·97) 0·95 (0·89–1·01)
Hospitalised clinical pneumonia 1095 (915) 105·3 (88·0) 1030 (823) 79·1 (63·2) 0·72 (0·65–0·79) 0·75 (0·69–0·82)
Hypoxic clinical pneumonia 134 (112) 12·9 (10·8) 74 (55) 5·7 (4·2) 0·39 (0·28–0·54) 0·44 (0·33–0·59)
Age 12–23 months
Radiological pneumonia with 
consolidation
189 (149) 15·3 (12·1) 161 (124) 10·2 (7·9) 0·65 (0·51–0·83) 0·67 (0·54–0·82)
Hospitalised radiological 
pneumonia with consolidation
156 (123) 12·6 (9·9) 128 (100) 8·1 (6·3) 0·64 (0·49–0·83) 0·64 (0·51–0·82)
Clinical pneumonia 1149 (906) 92·9 (73·3) 1490 (1187) 94·4 (75·2) 1·03 (0·94–1·12) 1·02 (0·94–1·10)
Hospitalised clinical pneumonia 687 (542) 55·6 (43·8) 691 (533) 43·8 (33·8) 0·77 (0·68–0·87) 0·79 (0·71–0·88)
Hypoxic clinical pneumonia 82 (65) 6·6 (5·3) 32 (21) 2·0 (1·3) 0·25 (0·15–0·41) 0·31 (0·20–0·46)
Age 2–4 years
Radiological pneumonia with 
consolidation
172 (148) 5·3 (4·6) 125 (97) 2·8 (2·1) 0·47 (0·35–0·62) 0·52 (0·40–0·67)
Hospitalised radiological 
pneumonia with consolidation
138 (119) 4·3 (3·7) 105 (81) 2·3 (1·8) 0·49 (0·36–0·66) 0·54 (0·41–0·72)
Clinical pneumonia 930 (796) 28·8 (24·7) 1307 (1034) 28·9 (22·9) 0·93 (0·84–1·03) 1·00 (0·91–1·10)
Hospitalised clinical pneumonia 583 (499) 18·1 (15·5) 609 (475) 13·5 (10·5) 0·68 (0·59–0·78) 0·75 (0·66–0·84)
Hypoxic clinical pneumonia 44 (38) 1·4 (1·2) 32 (24) 0·7 (0·5) 0·45 (0·26–0·79) 0·52 (0·31–0·86)
Age 2–59 months
Radiological pneumonia with 
consolidation
575 (477) 10·5 (8·7) 519 (398) 7·0 (5·4) 0·62 (0·54–0·71) 0·67 (0·60–0·76)
Hospitalised radiological 
pneumonia with consolidation
478 (396) 8·7 (7·2) 411 (318) 5·6 (4·3) 0·60 (0·51–0·69) 0·64 (0·56–0·73)
Clinical pneumonia 3782 (3124) 68·8 (56·8) 4815 (3834) 65·1 (51·8) 0·91 (0·87–0·96) 0·95 (0·91–0·99)
Hospitalised clinical pneumonia 2368 (1958) 43·1 (35·6) 2332 (1832) 31·5 (24·8) 0·70 (0·65–0·74) 0·73 (0·69–0·78)
Hypoxic clinical pneumonia 261 (215) 4·7 (3·9) 139 (100) 1·9 (1·4) 0·35 (0·27–0·44) 0·40 (0·32–0·49)
Age 5–14 years
Radiological pneumonia with 
consolidation
59 (66) 0·7 (0·8) 56 (41) 0·5 (0·4) 0·48 (0·32–0·70) 0·73 (0·51–1·05)
Hospitalised radiological 
pneumonia with consolidation
48 (54) 0·6 (0·6) 46 (34) 0·4 (0·3) 0·48 (0·31–0·74) 0·73 (0·49–1·10)
Clinical pneumonia 203 (233) 2·4 (2·7) 264 (189) 2·4 (1·7) 0·62 (0·51–0·75) 1·00 (0·86–1·20)
Hospitalised clinical pneumonia 110 (127) 1·3 (1·5) 81 (59) 0·7 (0·5) 0·36 (0·26–0·49) 0·57 (0·42–0·75)
Hypoxic clinical pneumonia 7 (8) 0·08 (0·09) 2 (2) 0·02 (0·02) 0·19 (0·04–0·90) 0·27 (0·06–1·19)
The baseline period was May 12, 2008, to May 11, 2010. Case counts are adjusted for temporal trends in the rate of patients meeting criteria for referral to surveillance clinicians and rounded to the nearest 
integer. CIs are calculated using an inflated variance due to over-dispersion in the 2–4 years age group. IRR=incidence rate ratio.
Table 4: Numbers of cases and incidence of pneumonia endpoints in the baseline period and in 2016–17 after vaccine introduction
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elimination of vaccine-type IPD in the 2–11 month age 
group. These findings are reassuring as our earlier 
analysis showed persisting PCV13-type IPD in young 
children.5 Similar observations have been made in other 
settings.12–14 In coastal Kenya, 5 years after the introduction 
of PCV10 with catch-up vaccination to 5 years of age, 
vaccine-type IPD in the under-5 year age group declined 
by 92% and all IPD by 68%.4 The difference between our 
91% reduction in PCV13-type IPD in the 2–23 month age 
group and the documented 57% reduction in South Africa 
seems to be primarily a result of the 8 years of vaccine use 
in The Gambia versus only 1 year at the time of the South 
African analysis.3
We did not observe significant serotype replacement 
disease. Secular trends might have contributed to this 
finding and study power was limited by the number of cases. 
Similar observations of limited serotype replacement in 
children have been made in some settings4,12 with 
significant replacement disease in others.18,19 Serotype 
replacement remains a concern, particularly in older age 
groups in high-income countries.19
The greater impact seen after 8 years of PCV 
introduction compared to our earlier estimates shows 
that programme impact continued to increase, even 
after 4 years of vaccine introduction. The 80% reduction 
in all IPD in the 2–59 month age group was greater than 
our previously reported 55% decline after 4 years of 
PCV7 or PCV13 introduction. This contrasts with the 
rapid impact of PCV10 introduction with catch-up 
immuni sation to age 5 years in Kilifi, Kenya, where 
vaccine-type IPD in young children declined to zero after 
only 2 years.4 In Basse, maximal programmatic impact 
in the under-5 year age group was achieved 8 years after 
vaccine introduction. These findings argue for the use of 
catch-up programmes as is now recommended by 
WHO20 and supported by Gavi.21
Our finding of an 89% reduction in PCV13-type IPD in 
5–14 year olds is similar to findings in Kenya where a 
92% reduction in PCV10-type IPD was observed.4 We 
also found reductions in all IPD and radiological 
pneumonia in the 5–14 year age group, although the 
reductions were not statistically significant. Investigators 
in Kenya did observe significant reductions in all IPD in 
this age group12 but declines in radiological pneumonia 
were not significant.16 The power of our study to detect 
vaccine impact in older children was limited by small 
numbers of cases and further surveillance is needed to 
confirm the indirect impact of the standard schedule in 
Figure 2: Adjusted annual incidence of invasive pneumococcal disease and pneumonia endpoints in Basse Health and Demographic Surveillance System 2008–17
Radiological pneumonia with consolidation (A). Clinical pneumonia (B). Hypoxic pneumonia (C). Invasive pneumococcal disease (D). Vaccine-type invasive pneumococcal disease (E). Non-vaccine 
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settings of high transmission, such as the African 
meningitis belt.
In contrast to our previous analysis we are now able to 
confirm PCV13 impact against serotype 1, which is an 
important cause of disease in low-income settings. 
Similar impact has been reported elsewhere.3,13,14 Our 
observation is important as it supports the argument that 
serotype 1 disease can be prevented in this setting 
without requiring a booster dose.22
Even though our finding of a 33% decline in radiological 
pneumonia in the 2–59 month age group was greater 
than the previously reported 24% decline, it is lower than 
the 47% reduction observed in Israel16 and 48% reduction 
in Kenya.23 Given that the routine use of PCV is associated 
with indirect effects in addition to direct protection, and 
our use of a PCV against 13 serotypes, we expected the 
reduction in radiological pneumonia to be greater than 
the 37% efficacy measured in the Gambian PCV9 trial. A 
temporal increase in the PCV13 period in the proportion 
of children presenting with respiratory symptoms 
who have radiological pneumonia might explain this 
observation. Such a change may have been related to a 
temporal increase in respiratory viral disease.
The greater period of observation in this analysis 
allowed us to document a 5% decline in all clinical 
pneumonia in the 2–59 month age group, which was not 
evident in our previous report, and a 27% reduction in 
hospitalised clinical pneumonia (previously reported 
8% reduction), we could also confirm a substantial 
60% decline in hypoxic pneumonia (previously reported 
65% reduction). The similarity to previous estimates 
against hypoxic pneumonia is likely a result of similar 
high coverage of PCV13 in the important 2–23 month 
age group during the period covered by our previous 
report. Indeed, our study supports the usefulness of 
hypoxic clinical pneumonia as an endpoint to assess 
pneumonia vaccines, especially in settings where 
radiology is not reliably available. The relatively low 
impact against clinical pneumonia is consistent with the 
PCV9 efficacy trial.24 The reason for this is unclear and 
may include the overlap of symptoms and signs of 
pneumonia with other diseases. Given the high burden 
of mortality associated with clinical pneumonia these 
children warrant further research.
Our study has several strengths. All screening, clinical 
investigation, case definitions, and laboratory practices 
were standardised and consistently applied throughout.7 
The very low proportion of infants who received sub-
stantially delayed second or third doses of PCV confirms 
that our results relate to the use of a three-dose schedule 
without booster or catch-up dose. However, there are 
some limitations. There were only 16 months of 
surveillance before the introduction of PCV7 and we 
specified a 2-year baseline period, based on the low 
proportion of children who had received at least two doses 
for several months after vaccine introduction. Before-
and-after studies are prone to bias and confounding due 
to changes in factors apart from vaccination. Our analysis 
provided some reassurance in this regard, with stable 
incidence of the control condition of non-pneumococcal 
bacteraemia, and no change in estimates in stratified 
analyses.
The substantial vaccine impact that we observed in The 
Gambia resulted from a PCV programme using a 
standard schedule of three primary doses without 
catch-up immunisation, the approach used in almost all 
low-income countries. Thus, given our findings, and the 
similar distributions of IPD serotypes elsewhere in 
Africa,3,4 and in South Asia,25 our data have important 
implications for EPI programmes globally. Programmes 
that introduce PCV with reasonable coverage and 
timeliness can expect substantial reductions in pneu-
mococcal disease and severe pneumonia; countries 
should consider catch-up vaccination when introducing 
PCV; and continued surveillance is needed to monitor for 
serotype replacement and determine whether indirect 
effects in older age groups will develop over a longer 
period of time. Our data will provide valuable information 
to countries that are yet to introduce PCV and those 
which have introduced it but are considering whether to 
maintain vaccination when they transition from Gavi 
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